Systemic Lupus Erythematosus (SLE) Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Systemic Lupus Erythematosus (SLE) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)+1 more
Polina Stepensky60 enrolled1 locationNCT07085676
Recruiting
Phase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Myasthenia GravisSystemic Lupus Erythematosus (SLE)Multiple Sclerosis (MS)+3 more
RenJi Hospital30 enrolled1 locationNCT06249438
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Early Phase 1

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology34 enrolled1 locationNCT06653556
Recruiting
Not Applicable

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySjogren's Syndrome+3 more
Shanghai Changzheng Hospital6 enrolled1 locationNCT06373081